Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2012 1
2013 1
2014 4
2015 9
2016 7
2017 6
2018 6
2019 4
2020 5
2021 7
2022 3
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Sex differences in kidney metabolism may reflect sex-dependent outcomes in human diabetic kidney disease.
Clotet-Freixas S, Zaslaver O, Kotlyar M, Pastrello C, Quaile AT, McEvoy CM, Saha AD, Farkona S, Boshart A, Zorcic K, Neupane S, Manion K, Allen M, Chan M, Chen X, Arnold AP, Sekula P, Steinbrenner I, Köttgen A, Dart AB, Wicklow B, McGavock JM, Blydt-Hansen TD, Barrios C, Riera M, Soler MJ, Isenbrandt A, Lamontagne-Proulx J, Pradeloux S, Coulombe K, Soulet D, Rajasekar S, Zhang B, John R, Mehrotra A, Gehring A, Puhka M, Jurisica I, Woo M, Scholey JW, Röst H, Konvalinka A. Clotet-Freixas S, et al. Among authors: barrios c. Sci Transl Med. 2024 Mar 6;16(737):eabm2090. doi: 10.1126/scitranslmed.abm2090. Epub 2024 Mar 6. Sci Transl Med. 2024. PMID: 38446901
A new approach to prostate cancer screening.
Filella X, González Á, Augé JM, Barco A, Carbonell R, Gaspar MJ, Martínez-Peinado A, Barrios CP, Sánchez-Carbayo M, Santotoribio JD, Trapé J; Comisión de Marcadores Biológicos de Cáncer, SEQCML. Filella X, et al. Among authors: barrios cp. Adv Lab Med. 2023 Aug 3;4(3):207-211. doi: 10.1515/almed-2023-0082. eCollection 2023 Sep. Adv Lab Med. 2023. PMID: 38075179 Free PMC article.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Predictive metabolites for incident myocardial infarction: a two-step meta-analysis of individual patient data from six cohorts comprising 7897 individuals from the COnsortium of METabolomics Studies.
Nogal A, Alkis T, Lee Y, Kifer D, Hu J, Murphy RA, Huang Z, Wang-Sattler R, Kastenmüler G, Linkohr B, Barrios C, Crespo M, Gieger C, Peters A, Price J, Rexrode KM, Yu B, Menni C. Nogal A, et al. Among authors: barrios c. Cardiovasc Res. 2023 Dec 30;119(17):2743-2754. doi: 10.1093/cvr/cvad147. Cardiovasc Res. 2023. PMID: 37706562 Free PMC article.
Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy.
Sevillano AM, Caravaca-Fontán F, Cordero Garcia-Galan L, Fernandez-Juarez G, Lopez-Revuelta K, Guzmán DA, Martín-Reyes G, Quintana LF, Rodas LM, Sanchez de la Nieta MD, Rabasco C, Espinosa M, Diaz-Encarnación M, San Miguel L, Barrios C, Rodriguez E, Garcia P, Valera A, Peña JK, Shabaka A, Velo M, Sierra M, Gonzalez F, Fernandez-Reyes MJ, Heras M, Delgado P, Gutierrez E, Moreno JA, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Sevillano AM, et al. Among authors: barrios c. Kidney Int Rep. 2023 Jun 5;8(8):1596-1604. doi: 10.1016/j.ekir.2023.05.027. eCollection 2023 Aug. Kidney Int Rep. 2023. PMID: 37547537 Free PMC article.
IgG N-glycans are associated with prevalent and incident complications of type 2 diabetes.
Memarian E, Heijmans R, Slieker RC, Sierra A, Gornik O, Beulens JWJ, Hanic M, Elders P, Pascual J, Sijbrands E, Lauc G, Dotz V, Barrios C, 't Hart LM, Wuhrer M, van Hoek M. Memarian E, et al. Among authors: barrios c. Diabetes Metab Res Rev. 2023 Oct;39(7):e3685. doi: 10.1002/dmrr.3685. Epub 2023 Jul 9. Diabetes Metab Res Rev. 2023. PMID: 37422864
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
56 results